MORGAN STANLEY PLC/CALL/MEDTRONIC/105/0.1/20.12.24 Share Price

Warrant

DE000MB8SL21

Real-time Bid/Ask 17:57:39 26/06/2024 BST
0.046 EUR / 0.049 EUR +2.13% Intraday chart for MORGAN STANLEY PLC/CALL/MEDTRONIC/105/0.1/20.12.24
Current month+4.44%
1 month-4.08%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
26/06/24 0.045 -4.26%
25/06/24 0.047 -6.00%
24/06/24 0.05 -5.66%
21/06/24 0.053 +20.45%
20/06/24 0.044 +15.79%

Delayed Quote Börse Stuttgart

Last update June 26, 2024 at 01:42 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying MEDTRONIC PLC
Issuer Morgan Stanley
WKN MB8SL2
ISINDE000MB8SL21
Date issued 14/07/2023
Strike 105 $
Maturity 20/12/2024 (177 Days)
Parity 10 : 1
Emission price 0.4
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.47
Lowest since issue 0.034
Spread 0.003
Spread %6.12%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
80.41 USD
Average target price
94.02 USD
Spread / Average Target
+16.93%
Consensus